Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.

Joint pain is often dismissed as aging, overuse or a minor injury. But for some people it is the first sign of inflammatory ...

The availability of TNF inhibitor biosimilars and the cost of treating ‘difficult-to-treat’ RA are making first-line TNF inhibition in early RA more attractive in the UK.

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associated companies) announced that the US ...

SALT LAKE CITY, UT, UNITED STATES, March 16, 2026 /EINPresswire.com/ -- The National Psoriasis Foundation (NPF) will ...

A new case study documents six months of complete pain relief in an 80-year-old man with arthritis, achieved without ...

Early intensive treatment for PsA with csDMARDs or 6 months of TNFi is superior to standard step-up care, and better outcomes ...

BITS Pilani's new nanomedicine gel shows promising preclinical results for rheumatoid arthritis treatment, enhancing drug delivery and reducing inflammation.

Jayant Mishra said he was approved for a copay card covering $9,450 a year. He didn't realize how fast the money would run out.

The U.S. Food and Drug Administration has approved Deucravacitinib (Sotyktu) for the treatment of adults with Psoriatic Arthritis. This oral drug is a selective TYK2 inhibitor and had ...

The knees are among the most underrated joints, which are responsible for bearing your entire body weight – Dr Rathi explains why knees start weakening early.